Aptima® Sexual and Vaginal Health Solutions

Rely on excellent sensitivity and specificity for your sexual and vaginal health testing needs.

Assay boxes in lab background

The most comprehensive sexual and vaginal health molecular menu.

Hologic offers the most comprehensive sexual and vaginal health portfolio that allows you to automate molecular testing workflows while instilling confidence in your clinical results. 

Multitest Diagram

One Sample, Multiple Results

With innovative nucleic acid amplification test (NAAT) and a single collection device, the Aptima® Multitest Swab simplifies testing by helping to detect up to 7 infections and disease states from just 1 vaginal swab.1-5

Expert Partner

Through continuous clinical research and trusted testing solutions, Hologic supports our partners in the fight against sexually transmitted infections (STIs) and accurate detection of vaginitis.

Proven Performance

Our sexual and vaginal health portfolio leverages best-in-class technology to provide timely and reliable results to patients.
 

Streamlined Workflow

The Aptima sexual and vaginal health portfolio can run alongside multiple disease areas on our fully automated Panther® Scalable Solutions.

Evolve Your Offerings with Aptima Assays

7 infections and disease states

can be detected with the Aptima sexual and vaginal health portfolio to support your testing needs. 

35 years of experience

in sexual and vaginal health molecular testing and helping stop the spread of disease.

A Comprehensive, Flexible Menu

By expanding access to timely and accurate results, Hologic empowers patients to protect their sexual and reproductive health.

Aptima Combo 2® assay (for chlamydia / gonorrhea)

Detects chlamydia and gonorrhea from a single sample. By using this highly specific and sensitive test, laboratories can improve workflow while allowing healthcare professionals to identify and treat patients with these often-asymptomatic infections to prevent long-term health consequences.1

Assay box on white background

Aptima® Trichomonas vaginalis assay

The first NAAT cleared by the FDA to test patients with or without symptoms for trichomoniasis. This test delivers up to 100% sensitivity and detects infections missed by traditional methods to improve overall patient care.5

Assay box on white background

Aptima® Mycoplasma genitalium assay

When identifying Mycoplasma genitalium, the test you choose matters. A highly sensitive rRNA test is needed for an accurate diagnosis, and NAAT is the most effective way to identify this STI. Hologic developed the first FDA-cleared sample-to-result test to detect this highly prevalent STI.2

Assay box on white background

Aptima® Herpes Simplex Viruses 1 & 2 assay

Provides specific knowledge required for healthcare professionals to better manage treatment for patients and provide targeted counseling based on the HSV infection type.6

Assay box on white background

Aptima® BV assay

Demonstrates excellent sensitivity and specificity, due to its proprietary quantitative algorithm and assay design, targeting Gardnerella vaginalis, Atopobium vaginae, and Lactobacillus species. A simple qualitative BV positive or negative result is returned.4

Assay box on white background

Aptima® CV/TV assay

Detects and differentiates microorganisms associated with vulvovaginal candidiasis (candida vaginitis or "CV”), commonly known as a yeast infection and trichomoniasis or “TV,” sometimes referred to as “trich.”3

Assay box on white background

The Significance of Diagnostic Testing in Women’s Health: Mycoplasma genitalium

Dr. Kyle Bukowski*, Chief Medical Officer for Planned Parenthood of Maryland, discusses real-world data reflective of current practices in the U.S. for Mycoplasma genitalium.

Increasing Certainty in Sexual & Vaginal Health

The Aptima sexual and vaginal health portfolio represents a comprehensive menu to champion women’s health worldwide. By supporting sexual health testing with innovative technology and a fully automated, sample-to-result platform, we are helping advance early detection and treatment.

Hologic is committed to protecting sexual and reproductive health by preventing the spread of STIs and vaginitis. We are continuously investing in R&D efforts designed to deliver new products to help healthcare providers and laboratories provide better patient care, now and in the future.  

Timeline

*Speaker and consultant for Hologic, Inc.
    *The Aptima Zika Virus assay: This test has not been FDA cleared or approved; This test has been authorized by FDA under an EUA for use by authorized laboratories; This test has been authorized only for the detection of RNA from Zika virus and diagnosis of Zika virus infection, not for any other viruses or pathogens; and this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under section 564(b)(1) of the Act, 21 U.S.C.§ 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
    † Speaker and consultant for Hologic, Inc.
    References: 1. Aptima Combo 2 Assay [package insert]. AW-20535, San Diego,CA; Hologic, Inc., 2022. 2. Aptima Mycoplasma genitalium assay [package insert]. AW-17946, San Diego, CA; Hologic, Inc., 2019. 3. Aptima CV/TV assay [package insert]. AW-18812, San Diego, CA;Hologic, Inc., 2021 4. Aptima BV assay [package insert]. AW-18811, San Diego, CA; Hologic, Inc., 2020. 5. Aptima Trichomonas vaginalis Assay [package insert]. 503684, San Diego, CA; Hologic, Inc., 2020. 6. Aptima HSV 1 & 2 assay [package insert]. AW-15346-001, San Diego, CA; Hologic, Inc., 2019. 7. CDC. Incidence, Prevalence, and Cost of Sexually Transmitted Infection in the United States. Last reviewed: March 16, 2022. Accessed July 7, 2022. https://www.cdc.gov/nchhstp/newsroom/fact-sheets/std/STI-Incidence-Prevalence-Cost-Factsheet.html [cdc.gov]8. Aptima Zika virus assay [package insert]. AW-15406, San Diego, CA; Hologic, Inc., 2018.